Bristol Myers Squibb Co.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1101221083
USD
51.95
0.99 (1.94%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Bristol Myers Squibb Co. stock-summary
stock-summary
Bristol Myers Squibb Co.
Pharmaceuticals & Biotechnology
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.
Company Coordinates stock-summary
Company Details
430 E 29th St Fl 14 , NEW YORK NY : 10016-8367
stock-summary
Tel: 1 212 54640001 609 2527509
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 247 Schemes (34.8%)

Foreign Institutions

Held by 593 Foreign Institutions (19.79%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Giovanni Caforio
Chairman of the Board, Chief Executive Officer
Dr. Vicki Sato
Lead Independent Director
Mr. Peter Arduini
Independent Director
Mr. Robert Bertolini
Independent Director
Mr. Michael Bonney
Independent Director
Mr. Matthew Emmens
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
12,269 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,313 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 127,940 Million (Large Cap)

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

80.34%

stock-summary
Debt Equity

2.05

stock-summary
Return on Equity

51.19%

stock-summary
Price to Book

7.34